C3.ai Announces COVID-19 Grand Challenge Winners
8.12.2020 17:00:00 EET | Business Wire | Press release
C3.ai, a leading enterprise artificial intelligence (AI) software provider for accelerating digital transformation, today announced the winners of the C3.ai™ COVID-19 Grand Challenge. Launched on Sept. 15, the global competition encouraged developers, data scientists, students, and creative minds to build world-class data science techniques and strategies that accelerate novel COVID-19 research and drive smart and safe decision-making. The C3.ai COVID-19 Grand Challenge represents an opportunity to inform decision makers at the local, state, and federal levels and transform the way the world confronts this pandemic.
After a rigorous review process, the judging panel selected seven research projects for recognition. Judges assessed how well the entries leveraged data science techniques to derive insights that were not apparent before. The judges selected submissions that were most likely to unlock significant public health and economic benefits.
A total of $200,000 in cash prizes will be awarded to these research teams. Each has developed meaningful data-driven insights that will help the global community understand and mitigate not only the spread of COVID-19, but also prepare the world to fight future pandemics, improve the medical community’s ability to respond, and help policymakers navigate decisions about COVID-19.
C3.ai Grand Challenge Award Winners:
Grand Prize - $100,000
- Combined Diagnostics - Modeling Population Heterogeneity and Personalized COVID Diagnostics. Predicts an individual’s infectious and susceptibility status and probability of having COVID-19. The team applied the Bayesian Stochastic Expectation-Maximization method to demographics, individual health characteristics, and behavioral and geographical data to provide personalized estimates for each individual’s infectious and susceptibility statuses. (Freddy Bunbury - Carnegie Institution for Science, Nina Miolane - University of California, Santa Barbara, and Claire Donnat - University of Chicago)
“Any return to normality relies on accurately determining who might have COVID-19. Demographics, individual health characteristics, and behavioral and geographical data considerably alter one’s risk of catching, suffering from, and spreading the virus,” said Freddy Bunbury, post-doctoral researcher at the Carnegie Institution for Science. “Knowing this, we developed a machine learning model that is reactive, granular, and even personalized to help individuals, and – by extension – society, compute with greater accuracy the probability of having COVID-19. By intelligently combining these disparate data sources, we aim to more robustly capture people’s individual likelihood of having and spreading the disease, reduce false test results, and inform disease transmission models.”
“This project has huge potential to make an immediate impact on the pandemic with its approach to generating meaningful results from COVID testing,” said Thomas M. Siebel, CEO of C3.ai. “This is an unprecedented opportunity to apply informed decision-making based on data to enable daily life and business operations to continue, while effectively managing health risks.”
Second-Place Awards - $25,000 each
- DeepOutbreak: Framework for Forecasting Dynamics of COVID-19 and Co-Evolving Diseases. Models the progression of COVID-19 and symptomatically similar co-evolving influenza-like illnesses, as well as hospitalization and mortality rates. Designed to optimize healthcare deployment, which is especially important with hospitalizations resurging and healthcare workers increasingly becoming ill. (Alexander Rodriguez, Nikhil Muralidhar, Bijaya Adhikari, Naren Ramakrishnan, and B. Aditya Prakash - U.S.)
- Assessing Conservation Level of Therapeutic and Vaccine Targets of COVID-19. Predicts the effectiveness of vaccines and therapeutics by genome sequences and prioritizes relevant treatments to inform drug and vaccine development. (Yuanfang Guan and Manqi Zhou - U.S.)
Third-Place Awards - $12,500 each
- Analysis of COVID-19 Policies’ Impact on the Population and the Economy . Calculates the impact of government policies on COVID-19 infection rates, stock prices, and a population’s mobility to inform governments about how policies affect people and the economy. (Niti Wattanasirichaigoon, Napat Ratanakul, and Apiwat Jaroonpol - U.S., Singapore, and Japan)
- COVIDProf: An Intelligent Q&A Chatbot Tuned to Deliver Scientific Research and Data Related to COVID-19 in Natural Language. Makes finding and understanding relevant COVID-19 scientific research and data easier for the average person through an intelligent Q&A chatbot. (Varsha Rao and Joy Yeh - Singapore and Japan)
- Structural Modeling of COVID Spread in Relation to Human Mobility . Models causal relationships between human mobility indicators (trips, distance traveled, staying at home, and social distancing) and COVID-19 spread to inform how policymakers should take action. (Rezwana Rafiq, Tanjeeb Ahmed, and Md Yusuf Sarwar Uddin - U.S.)
- The Center on Stochastic Modeling, Optimization, and Statistics (COSMOS) COVID -19 Linear Programming. Online tool for reopening communities that enables decision makers to study hypothetical scenarios to inform planning and protect high-risk individuals. (Victoria Chen, Yuan Zhou, Nilabh Ohol, Alireza Fallahi, and Amith Viswanatha - U.S.)
Award Criteria
The projects were reviewed on the basis of their scientific merit, the use of AI, machine learning, and/or other data science techniques in the project, and the incorporation of at least two data sources from the C3 AI® COVID-19 Data Lake.
The evaluation process also considered the extent to which the derived data science insights, if implemented at scale, will result in significant public health and economic benefit.
To learn more about the C3.ai COVID-19 Grand Challenge, please visit https://c3.ai/c3-ai-covid-19-grand-challenge/.
About C3.ai
C3.ai is a leading AI software provider for accelerating digital transformation. C3.ai delivers the C3 AI Suite for developing, deploying, and operating large-scale AI, predictive analytics, and IoT applications in addition to an increasingly broad portfolio of turnkey AI applications. The core of the C3.ai offering is a proprietary, model-driven AI architecture that dramatically enhances data science and application development.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201208005727/en/
Contact information
Lisa Kennedy
415-914-8336
pr@c3.ai
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
T964 Named as Uptime Institute Business Partner to Power Iraq’s Digital Infrastructure29.7.2026 10:02:00 EEST | Press release
Uptime Institute and Tech964 Holding Limited (T964), Iraq’s leading digital infrastructure company, today announced a landmark strategic partnership to accelerate Iraq’s digital transformation. The partnership combines the world’s leading authority in digital infrastructure standards with the company building the critical infrastructure underpinning Iraq’s digital economy. The agreement was signed at the U.S. Chamber of Commerce U.S.-Iraq Business Summit on July 17, 2026, during the official U.S. visit of Iraqi Prime Minister Ali Al-Zaidi, at a historic summit that produced more than 50 agreements valued at over USD $60 billion and marked a powerful new era of economic cooperation between the United States and Iraq. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260728066813/en/ T964 named as Uptime Institute Business Partner to power Iraq's digital infrastructure, landmark agreement signed at U.S. Chamber of Commerce U.S.-
PK MED Strengthens Its Strategic and Scientific Governance to Support the Development of Its Therapeutic Micro-implants29.7.2026 10:00:00 EEST | Press release
PK MED, a French biotechnology company founded by Truffle Capital (founder of Abivax and Carvolix), developing therapeutic micro-implants to address major medical needs, today announces a significant strengthening of its governance. The company is strengthening the structure of its Board of Directors and Scientific Advisory Board to support the upcoming Phase 2 entry of its most advanced drug candidate, ARTHRELIS (treatment of gout flares), and to accelerate the preclinical development of ENGRAFTIS (treatment of poor graft function following bone marrow transplantation). The Board of Directors of PK MED welcomes four key new members: François Romaneix, appointed Chairman of the Board of Directors. Senior Partner at Truffle Capital, former CEO of the French National Authority for Health (HAS), and former Deputy CEO of the Institut Pasteur, he brings his strategic vision for market access and healthcare corporate governance. Isabelle Buckle, PhD, Board Member. With more than three decade
ELFA Vape Aerosols Less Harmful Than Cigarette Smoke: Study29.7.2026 10:00:00 EEST | Press release
Levels of 17 constituents in aerosols from ELFA, a pod system vape by ELFBAR, are undetected or substantially lower than those in cigarette smoke, reveals the latest peer-reviewed study published by iScience, a scientific journal. Aerosols in this study are generated by facilities under standardized laboratory conditions. The tests involve 17 cigarette smoke-related analytes during vaporization of vape liquid from ELFA’s pods in four flavors, including Super Tobacco, Spearmint, Strawberry Ice and Watermelon. Findings indicate that adult smokers completely transitioning to ELFA pod system could reduce, or even eliminate, their exposure to multiple harmful constituents compared with consuming combustible cigarettes. “This study adds to the growing scientific evidence supporting the effective role vaping products play in reducing, or even eliminating, exposure to harmful chemical substances for adult smokers,” said an ELFBAR spokesperson. “Providing adult users with quality cessation alte
OpenGate Capital Executes Agreement to Acquire Merak, the Global Rail HVAC Business of Knorr-Bremse29.7.2026 09:00:00 EEST | Press release
OpenGate Capital (“OpenGate”), a global private equity firm, announced today that it has signed a definitive agreement to acquire Merak, the global rail HVAC business of Knorr-Bremse, a publicly listed German industrial company. Terms of the transaction were not disclosed. Headquartered in Getafe, Spain, Merak is a leading global provider of HVAC systems for rail vehicles, with facilities across Spain, Austria, Australia, the United States, China and India. The company offers a comprehensive portfolio of HVAC solutions spanning original equipment, aftermarket services, spare parts, system modernization and overhaul. Built on more than 60 years of engineering expertise, Merak serves a global installed base and maintains long standing relationships with many of the world's leading rolling stock manufacturers. "Merak is a high quality business with a market leading position, differentiated technology and a global customer base built over decades," said Joshua Adams, Partner at OpenGate Ca
Bureau Veritas: Delivering on Our Commitments With Higher Sequential Organic Growth in Q2 and Continuous Margin Improvements29.7.2026 08:30:00 EEST | Press release
Bureau Veritas (BOURSE:BVI): H1 2026 key figures1 › Revenue of EUR 3,258.4 million in H1 2026, up 2.1% year-on-year and up 5.0% organically (with a sequential improvement in Q2 2026 at 5.5% organic growth), › Adjusted operating profit of EUR 506.5 million, up 3.1% versus EUR 491.5 million in H1 2025, representing an adjusted operating margin of 15.5%, up 15 basis points year-on-year and up 29 basis points at constant currency, › Operating profit of EUR 430.8 million, down 16.0% versus EUR 513.1 million in H1 20252, › Adjusted net profit of EUR 303.8 million, up 3.9% versus EUR 292.4 million in H1 2025, › Adjusted EPS stood at EUR 0.68 in H1 2026, with a 4.8% increase on a reported basis versus H1 2025 (EUR 0.65 per share) and 9.8% at constant currency, › Attributable net profit of EUR 237.9 million, down 26.2% versus EUR 322.3 in H1 2025, › Free Cash Flow of EUR 157.7 million, up 3.2% organically, and down 6.1% year-on-year due to forex evolutions, › Adjusted net debt/EBITDA ratio stoo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
